DIR Technologies has announced a five-year agreement with Pfizer, Inc. The agreement provides Pfizer access to DIR’s packaging technology, which includes first-to-industry inspection and quality control solutions. The two companies will also work together on the development of a new inspection technology based on DIR’s advanced high-speed imaging capabilities.
Among the products included in the agreement is DIR’s flagship Induction Integrity Verification System (I2VS). According to DIR, the I2VS is the first system in the global pharmaceuticals market “to perform in-line inspection on 100 percent of induction-sealed bottles at the speed of the machine throughput.” DIR also said that I2VS indicates the source of any potential faulty seals in real time, allowing the problem to be fixed immediately or prevented from occurring altogether.
CEO of DIR Technologies Roni Mansur said:
“Obviously, Pfizer is a well-established leader in pharmaceuticals manufacturing and part of our excitement in working with Pfizer is the company’s dedication to also being an industry pioneer in terms of technological advancement. Pfizer’s methodology of continuous improvement drives it to test and implement the best of cutting-edge solutions. It takes a true entrepreneurial spirit to lead the way and make a change, to implement technology that is different from the industry norm.”